For the starting dose of 2.5 mg, you are targeting 12.5 units, which sits exactly between the 12 and 13 unit lines
By activating both GIP and GLP-1 receptors, Tirzepatide promotes insulin secretion, inhibits glucagon release, and slows gastric emptying, ultimately leading to improved glycemic control and reduced appetite
Serious adverse events appear rare in the relatively short human studies available, but high-quality long-term safety data beyond one year are limited
The gravity measurements are starting to really upend this classical view, and it looks like it may just be more well mixed down there
Antithyroid drugs act by interfering with thyroid hormone synthesis
This is relevant for the short-acting GLP-1 agonists, whereas tachyphylaxis rapidly develops for the long-acting agonists [8]